Velcade (bortezomib), the first in a new class of investigational drugs known as proteasome
inhibitors, was approved for use in multiple myeloma in record-making time—only 4 months …

The ubiquitin-proteasome pathway (UPP) is the major non-lysosomal proteolytic system in
the cytosol and nucleus of all eukaryotic cells. Bortezomib (also known as PS-341 and …

The ubiquitin proteasome pathway plays a critical role in regulating many processes in the
cell which are important for tumour cell growth and survival. Inhibition of proteasome …

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers
apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib …

The development of the proteasome inhibitor bortezomib is a prime example of successful
bench-to-bedside research. NF-κB is implicated in the pathogenesis of multiple myeloma …

Proteasome inhibitors (PIs) are a proven class of therapeutic agents in the treatment of
cancers including multiple myeloma (MM), Waldenstrm macroglobulinemia, and mantle cell …

Proteasome inhibitors have revolutionized the treatment of multiple myeloma but have had
disappointing results when treating solid tumors. The work of Weyburne et al.(2017) …

Velcade (also known as PS-341 or Bortezomib) is a highly selective and reversible inhibitor
of the 26S proteasome and is approved for the treatment of patients with advanced multiple …

Bortezomib, a boronic acid, is a potent and selective proteasome inhibitor. The 20S
proteasome is an enzyme complex present in cells, and it degrades many cell-cycle control …

The ubiquitin proteasome system is an attractive pharmacological target for the treatment of
cancer. The proteasome inhibitor bortezomib has been approved for the treatment of …